Chau Sarah A, Herrmann Nathan, Chung Jonathan, Eizenman Moshe, Lanctôt Krista L
Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Can Geriatr J. 2018 Jun 30;21(2):139-142. doi: 10.5770/cgj.21.291. eCollection 2018 Jun.
The purpose of this pilot study was to explore the potential of eye-tracking technology in monitoring symptoms and predicting outcomes in apathetic Alzheimer's disease (AD) patients treated with methylphenidate (MTP).
Neuropsychological tests and eye-tracking measurements were completed at baseline and following at least four weeks of treatment with MTP (5-10 mg BID). Eye-movements were measured while patients viewed novel and social stimuli. Cognition, behavior, and apathy were assessed using the Standardized Mini-Mental State Exam (sMMSE), Neuropsychiatric Inventory, and Apathy Evaluation Scale (AES), respectively.
Nine patients were included in the analysis (age: median=75, interquartile range=8; sMMSE: median=22, interquartile range=14). Spearman correlations showed that improvement on the AES was associated with increased visual attention towards novel stimuli (ρ=-0.809, =.008). Additionally, lower baseline attention towards social images was associated with improvement on the AES (ρ=0.905, =.001).
Eye-tracking techniques can be developed as an objective and nonverbal method of monitoring symptoms and treatment outcomes in AD patients.
本初步研究的目的是探索眼动追踪技术在监测接受哌醋甲酯(MTP)治疗的淡漠型阿尔茨海默病(AD)患者症状及预测其预后方面的潜力。
在基线时以及接受MTP(5 - 10毫克,每日两次)至少四周治疗后,完成神经心理学测试和眼动追踪测量。在患者观看新异刺激和社交刺激时测量眼动。分别使用标准化简易精神状态检查(sMMSE)、神经精神科问卷和淡漠评定量表(AES)评估认知、行为和淡漠情况。
9名患者纳入分析(年龄:中位数 = 75,四分位间距 = 8;sMMSE:中位数 = 22,四分位间距 = 14)。Spearman相关性分析显示,AES得分的改善与对新异刺激视觉注意力的增加相关(ρ = -0.809,P = 0.008)。此外,对社交图像较低的基线注意力与AES得分的改善相关(ρ = 0.905,P = 0.001)。
眼动追踪技术可发展成为一种客观且非言语的方法,用于监测AD患者的症状及治疗效果。